Alzheimer’s disease research has attracted some of the most brilliant minds in medical research over the past 20 years. While researchers have learned a lot about the diseases, its pathology, and its triggers, relatively little progress has been in made on fighting the disease.

The team behind experimental drug J147 (1146963-51-0) decided to take a different approach. The early results have been impressive, and researchers are continuing to study how this new drug interacts with the different cells of the body.

 


 

Kodi J147?

 

J147 is a nootropics powder first developed in 2011. Researchers have found that the drug, across several different studies, can reverse memory loss and slow, or even reverse, Alzheimer’s in mice.

J147 powder is a phenyl hydrazide. It is derived from the curry spice component curcumin. It is a low toxicity. Despite some early concerns, J147 powder has not been shown to be carcinogenic. Researchers tested extensively for this possibility by examining the metabolites of J147 in human and mouse microsomes and mouse plasma.

The results showed that J147 is not metabolized to aromatic amines or hydrazines.

 


 

Traditional Approaches to Fighting Alzheimer’s

 

Most drugs developed in the past 20 years have been targeted on the amyloid plaque deposits in the brains of Alzheimer’s patients. This approach makes intuitive sense because these deposits are what choke the nerve cells to death.

However, after 20 years there has not been any significant progress in clinical trials with any of the drugs that target the plaque deposits.

A related approach has been to try and target the amyloid before it forms the plaque deposits. The amyloid destroys synapses before it forms into plaque clumps. However, even this earlier targeting has not proven to be effective.

Until the development of J147 (1146963-51-0), the actual treatment of Alzheimer’s was at a standstill. There wasn’t any clear path forward with any of the drugs that had been developed over the past 20 years and the pathology of the disease itself did not lend itself to any other obvious approaches.

 


 

How J147 (1146963-51-0) Works Against Alzheimer’s

 

The team behind J147 decided to take a different tact in the fight against Alzheimer’s. Instead of developing yet another drug that targeted amyloid, the team decided to focus on a major risk factor for Alzheimer’s. The biggest single risk factor is old age—so the team turned its efforts to anti-aging mechanisms.

The team created J147 by using cell-based screens against old-age brain toxicities. From these screens, they synthesized the J147 powder.

The J147 powder works by reducing the activity of the ATP synthase in the mitochondria. This protected neuronal cells from many of the age-related brain toxicities. Research indicated the reason this compound produces this neuroprotective effect is because of the role excitotoxicity plays in neuronal cell damage.

Neurons become damaged and are killed by the overactivation of the receptors for the excitatory neurotransmitter glutamate. J147 essentially slows down the processes that certain old-age brain toxicities speed up. This preserves the neurons and, even more remarkably, can also trigger the reversal of some of the more pronounced effects of Alzheimer’s.

 


 

J147 Works as an Anti-Aging Agent

 

The mechanics of J147 are nothing like the other Alzheimer’s drugs that have reached a similar stage of research. Because it doesn’t focus on the traditional pathology of the disease, but rather works to mitigate the dangers presented by the aging risk factor.

J147 works as an anti-aging agent. Left to its own devices, the human brain develops certain toxicities. It is these age-related toxicities that create the environment for Alzheimer’s to flourish. J147 turns back the clock on these toxicities, in turn this makes it harder for Alzheimer’s to do its work of deteriorating different memory systems.

It is probable that the approach pioneered by J147 will be useful for far more than just the fight against Alzheimer’s. Similar anti-aging agents may be able to target other toxicities that cause other diseases and ailments where age alone is a primary risk factor. J147 is not just an Alzheimer’s drug. It is really a drug that helps reverse aging itself.

 


 

J147 chipatala Mayesero

 

Even though J147 was first developed in 2011, it just now nearing approval for widespread clinical trials. At every step along the way, J147 has been shown to not only be incredibly effective, but it has also been shown to be stable.

Early concerns about the possibility of J147 being carcinogenic, or otherwise toxic, have been shown to be unfounded.

Researchers are anxious to get the clinical trials underway and almost everyone involved in Alzheimer’s research is hopeful that J147 will prove to be as effective in humans as it has been in mice and in laboratory simulations.

 


 

Preliminary J147 Findings

 

Early on researchers found that J147 (1146963-51-0) could prevent, and reverse, memory loss in mice that have the inherited version of Alzheimer’s. However, as hopeful as that result was, in humans, only about 1% of Alzheimer’s patients have the inherited version. The most common form of Alzheimer’s is associated not with a specific set of genetics, but with old age itself.

The team than studied the effects of J147 on a group of mice that age rapidly and experience a form of dementia that is similar to the age-related Alzheimer’s found in humans.

The results of this second study were also promising. J147 was able to rescue cognitive deficits, even when administered in the late stages of the disease. It improved memory in the mice and prevented further deterioration.

It was also found that when J147 was combined with donepezil it worked better for restoring contextual and cued memory. But, J147 alone was superior in restoring spatial memory.

 


 

What the Future Holds for J147 (1146963-51-0)

 

There is still a long road before J147 (1146963-51-0) will be available to treat most Alzheimer’s patients. First the drug must complete the rigorous clinical trial phase. Once the clinical trials have been peer reviewed, the process for FDA approval will begin.

Researchers are mindful of the urgent need for a meaningful treatment for Alzheimer’s disease, but they are also committed to not rushing the science. So far, all of the results for J147 are extremely positive and no other Alzheimer’s drug has ever looked this good this far into the process.

 


 

More about J147:

Mafuta akuluakulu a Tadalafil (Cialis) ufa hplc =99.5% | AASraw tadalafil powder

Buy high purity Tadalafil powder online:All things you should to know!!!

Tadalafil powder yogulitsa: Kodi mungasankhe bwanji tadalafil powder supplier?

 

Experimental Drug J147 Alzheimer’s Aging | AASraw

 


 

 

0 Likes
60 Views

Siyani A Comment

Chonde lowetsani dzina lanu. Chonde lowetsani imelo yeniyeni yolondola. Chonde lowetsani uthenga.

Captcha *